Biotech & AI drug discoveryNature Medicine

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

Nature Medicine published an author correction concerning a phase 1 trial paper on the FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma. The item provides no details on what was corrected.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-20T00:00:00+00:00

Published here2026-10-21T05:06:15+00:00

Original source

Nature Medicine

Media report · consult original reporting

Read the original ↗https://www.nature.com/articles/s41591-026-04757-0

Original headline

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.